3 active not recruiting, 3 withdrawn, 2 terminated, 1 completed. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 3, Withdrawn 3, Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 3 | Not yet recruiting 1, Recruiting 1, Terminated 1 |
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors Elraglusib Oral Tablets - Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Actuate Therapeutics Inc. | 100 | 2026-10-01 | 2026-07-20 |
| 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY) Retifanlimab, Chemotherapy, 9-ING-41 - Pancreatic Adenocarcinoma | Phase 1 | Recruiting | Anwaar Saeed | 12 | 2025-09-22 | 2026-09-24 |
| FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer FOLFIRNINOX, Losartan, 9-ING-41 - Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic | Phase 2 | Active not recruiting | Colin D. Weekes, M.D., PhD | 70 | 2022-03-21 | 2026-09-11 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma 9-ING-41, Retifanlimab, Gemcitabine - Pancreatic Adenocarcinoma | Phase 2 | Terminated | Anwaar Saeed | 7 | 2022-01-26 | 2025-07-17 |
| 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma 9-ING-41, Carboplatin, Pembrolizumab - Salivary Gland Cancer, Recurrent Salivary Gland Cancer | Phase 2 | Active not recruiting | Glenn J. Hanna | 32 | 2021-09-17 | 2026-08-07 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Actuate 1901: 9-ING-41 in Myelofibrosis Ruxolitinib, 9-ING-41 - Myelofibrosis | Phase 2 | Completed | Actuate Therapeutics Inc. | 17 | 2020-08-20 | 2024-02-07 |
| 9-ING-41 in Pediatric Patients With Refractory Malignancies. 9-ING-41, Irinotecan, Temozolomide - Refractory Cancer, Refractory Neoplasm | Phase 1 | Terminated | Actuate Therapeutics Inc. | 40 | 2020-06-05 | 2025-07-17 |
| 9-ING-41 in Patients With Advanced Cancers 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin. - Cancer, Pancreatic Cancer | Phase 2 | Active not recruiting | Actuate Therapeutics Inc. | 350 | 2019-01-04 | 2026-04-03 |
Bone Neoplasms (3) · Hereditary Sensory and Autonomic Neuropathies (3) · Neoplasm Metastasis (3) · Sarcoma (3) · Carcinoma, Adenoid Cystic (2) · Dermatofibrosarcoma (2) · Hemangiosarcoma (2) · Histiocytoma, Malignant Fibrous (2) · Leiomyosarcoma (2) · Liposarcoma (2) · Neoplasms (2) · Rhabdomyosarcoma (2) · Salivary Gland Neoplasms (2) · Sarcoma, Synovial (2) · Breast Neoplasms (1)
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (10) · Gemcitabine (4) · Carboplatin (3) · Albumin-Bound Paclitaxel (2) · Docetaxel (2) · Irinotecan (2) · Cyclophosphamide (1) · Doxorubicin (1) · Drug Therapy (1) · Lomustine (1) · Losartan (1) · Paclitaxel (1) · Taxes (1) · Temozolomide (1) · Topotecan (1)
United States (10) · Belgium (1) · Canada (1) · France (1) · Netherlands (1) · Portugal (1) · Spain (1)
Anwaar Saeed, MD (2) · Glenn J Hanna, MD (2) · Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Colin D Weekes, MD, PhD (1) · Don S Dizon, MD (1) · Galina G Lagos, MD (1)
PMID 24327518, PMID 27424289, PMID 28672195, PMID 29383130, PMID 29846250, PMID 31101621, PMID 31533931, PMID 31831767, PMID 31882719, PMID 28053024, PMID 31894292, PMID 29073967, PMID 30405781, PMID 30975030, PMID 31401903, PMID 35815408, PMID 36104795, PMID 41981308